Cargando…
Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy
BACKGROUND: Neoadjuvant treatment followed by esophagectomy is standard practice in locally advanced esophageal cancer. However, not all patients who started neoadjuvant treatment will undergo esophageal resection. The purpose of our study was to investigate the group of patients, scheduled for neoa...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537364/ https://www.ncbi.nlm.nih.gov/pubmed/31133018 http://dx.doi.org/10.1186/s12957-019-1630-8 |
_version_ | 1783421989884526592 |
---|---|
author | Depypere, Lieven Thomas, Melissa Moons, Johnny Coosemans, Willy Lerut, Toni Prenen, Hans Haustermans, Karin Van Veer, Hans Nafteux, Philippe |
author_facet | Depypere, Lieven Thomas, Melissa Moons, Johnny Coosemans, Willy Lerut, Toni Prenen, Hans Haustermans, Karin Van Veer, Hans Nafteux, Philippe |
author_sort | Depypere, Lieven |
collection | PubMed |
description | BACKGROUND: Neoadjuvant treatment followed by esophagectomy is standard practice in locally advanced esophageal cancer. However, not all patients who started neoadjuvant treatment will undergo esophageal resection. The purpose of our study was to investigate the group of patients, scheduled for neoadjuvant treatment followed by esophagectomy, who never made it to esophageal resection. METHODS: We retrospectively analyzed patients treated between 2002 and 2015 for locally advanced esophageal cancer, who did not undergo esophagectomy after neoadjuvant treatment. Subanalysis was performed according to time period (2002–2010 versus 2011–2015) and histology (adenocarcinoma versus squamous cell carcinoma). RESULTS: In 114 of 679 patients (16.8%), surgery was not performed after neoadjuvant treatment. Reasons for cancelation were disease progression (50 patients, 43.9%), poor general condition (26 patients, 22.8%), irresectability (14 patients, 12.3%), patients’ own decision (15 patients, 13.2%), and death during neoadjuvant treatment (9 patients, 7.9%). In the second time period, there were less irresectable tumors (17.7% versus 5.8%; p = 0.044). Median overall survival was not different over time (9.2 versus 12.5 months; p = 0.937). Irresectability (p = 0.032), patients’ refusal (p = 0.012), and poor general condition (p = 0.002) were more frequent as reasons for cancelation in squamous cell carcinoma patients. Median overall survival was, respectively, 12.5 and 9.9 months for adenocarcinoma and squamous cell carcinoma patients (p = 0.441). The majority of patients refusing surgery had a clinical complete response (73.3%). They had a median overall survival of 33.2 months. CONCLUSIONS: One in six patients starting neoadjuvant treatment for locally advanced esophageal cancer never made it to esophagectomy, more than half of them for oncological reasons, but also 1.3% because of death during treatment. Over time, irresectability as reason decreased. As a result, the relative weight of medical inoperability increased, indicating the importance of upfront testing of medical operability. Cancelation of surgery was significantly more common in patients with a squamous cell carcinoma, and this histology seems to represent a more complex oncological and functional entity. Refusal of esophagectomy based on clinical complete response showed a significant survival benefit compared to those who did not undergo esophagectomy because of other reasons. |
format | Online Article Text |
id | pubmed-6537364 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-65373642019-05-30 Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy Depypere, Lieven Thomas, Melissa Moons, Johnny Coosemans, Willy Lerut, Toni Prenen, Hans Haustermans, Karin Van Veer, Hans Nafteux, Philippe World J Surg Oncol Research BACKGROUND: Neoadjuvant treatment followed by esophagectomy is standard practice in locally advanced esophageal cancer. However, not all patients who started neoadjuvant treatment will undergo esophageal resection. The purpose of our study was to investigate the group of patients, scheduled for neoadjuvant treatment followed by esophagectomy, who never made it to esophageal resection. METHODS: We retrospectively analyzed patients treated between 2002 and 2015 for locally advanced esophageal cancer, who did not undergo esophagectomy after neoadjuvant treatment. Subanalysis was performed according to time period (2002–2010 versus 2011–2015) and histology (adenocarcinoma versus squamous cell carcinoma). RESULTS: In 114 of 679 patients (16.8%), surgery was not performed after neoadjuvant treatment. Reasons for cancelation were disease progression (50 patients, 43.9%), poor general condition (26 patients, 22.8%), irresectability (14 patients, 12.3%), patients’ own decision (15 patients, 13.2%), and death during neoadjuvant treatment (9 patients, 7.9%). In the second time period, there were less irresectable tumors (17.7% versus 5.8%; p = 0.044). Median overall survival was not different over time (9.2 versus 12.5 months; p = 0.937). Irresectability (p = 0.032), patients’ refusal (p = 0.012), and poor general condition (p = 0.002) were more frequent as reasons for cancelation in squamous cell carcinoma patients. Median overall survival was, respectively, 12.5 and 9.9 months for adenocarcinoma and squamous cell carcinoma patients (p = 0.441). The majority of patients refusing surgery had a clinical complete response (73.3%). They had a median overall survival of 33.2 months. CONCLUSIONS: One in six patients starting neoadjuvant treatment for locally advanced esophageal cancer never made it to esophagectomy, more than half of them for oncological reasons, but also 1.3% because of death during treatment. Over time, irresectability as reason decreased. As a result, the relative weight of medical inoperability increased, indicating the importance of upfront testing of medical operability. Cancelation of surgery was significantly more common in patients with a squamous cell carcinoma, and this histology seems to represent a more complex oncological and functional entity. Refusal of esophagectomy based on clinical complete response showed a significant survival benefit compared to those who did not undergo esophagectomy because of other reasons. BioMed Central 2019-05-27 /pmc/articles/PMC6537364/ /pubmed/31133018 http://dx.doi.org/10.1186/s12957-019-1630-8 Text en © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Depypere, Lieven Thomas, Melissa Moons, Johnny Coosemans, Willy Lerut, Toni Prenen, Hans Haustermans, Karin Van Veer, Hans Nafteux, Philippe Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy |
title | Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy |
title_full | Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy |
title_fullStr | Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy |
title_full_unstemmed | Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy |
title_short | Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy |
title_sort | analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537364/ https://www.ncbi.nlm.nih.gov/pubmed/31133018 http://dx.doi.org/10.1186/s12957-019-1630-8 |
work_keys_str_mv | AT depyperelieven analysisofpatientsscheduledforneoadjuvanttherapyfollowedbysurgeryforesophagealcancerwhonevermadeittoesophagectomy AT thomasmelissa analysisofpatientsscheduledforneoadjuvanttherapyfollowedbysurgeryforesophagealcancerwhonevermadeittoesophagectomy AT moonsjohnny analysisofpatientsscheduledforneoadjuvanttherapyfollowedbysurgeryforesophagealcancerwhonevermadeittoesophagectomy AT coosemanswilly analysisofpatientsscheduledforneoadjuvanttherapyfollowedbysurgeryforesophagealcancerwhonevermadeittoesophagectomy AT leruttoni analysisofpatientsscheduledforneoadjuvanttherapyfollowedbysurgeryforesophagealcancerwhonevermadeittoesophagectomy AT prenenhans analysisofpatientsscheduledforneoadjuvanttherapyfollowedbysurgeryforesophagealcancerwhonevermadeittoesophagectomy AT haustermanskarin analysisofpatientsscheduledforneoadjuvanttherapyfollowedbysurgeryforesophagealcancerwhonevermadeittoesophagectomy AT vanveerhans analysisofpatientsscheduledforneoadjuvanttherapyfollowedbysurgeryforesophagealcancerwhonevermadeittoesophagectomy AT nafteuxphilippe analysisofpatientsscheduledforneoadjuvanttherapyfollowedbysurgeryforesophagealcancerwhonevermadeittoesophagectomy |